|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:activities
|
parathyroid hormone analog
|
|
gptkbp:appointed_by
|
subcutaneous injection
|
|
gptkbp:approves
|
gptkb:2002
gptkb:FDA
|
|
gptkbp:availability
|
prescription only
|
|
gptkbp:brand
|
teriparatide
|
|
gptkbp:class
|
hormone replacement therapy
anabolic agent
|
|
gptkbp:clinical_trial
|
Phase 3
reduce fracture risk
increase bone density
|
|
gptkbp:contraindication
|
hypercalcemia
bone metastases
paget's disease
|
|
gptkbp:dosage_form
|
gptkb:software_framework
|
|
gptkbp:duration
|
up to 2 years
|
|
gptkbp:education
|
injection technique
recognizing side effects
importance of adherence
|
|
gptkbp:formulation
|
pre-filled pen
|
|
gptkbp:frequency
|
once daily
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Forteo
|
|
gptkbp:ingredients
|
teriparatide
|
|
gptkbp:interacts_with
|
gptkb:digoxin
diuretics
other calcium supplements
|
|
gptkbp:invention
|
gptkb:2023
|
|
gptkbp:is_monitored_by
|
renal function
bone density
calcium levels
|
|
gptkbp:is_used_for
|
osteoporosis
|
|
gptkbp:manufacturer
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:marketed_as
|
gptkb:legislation
gptkb:United_States
gptkb:Native_American_tribe
|
|
gptkbp:pharmacokinetics
|
excreted in urine
subcutaneous absorption
metabolized in liver
|
|
gptkbp:population
|
postmenopausal women
men at high risk of fracture
|
|
gptkbp:price
|
high
|
|
gptkbp:provides_information_on
|
gptkb:American_Association_of_Clinical_Endocrinologists
gptkb:National_Osteoporosis_Foundation
|
|
gptkbp:safety_features
|
not for use in children
monitor for signs of allergic reactions
risk of osteosarcoma
|
|
gptkbp:side_effect
|
dizziness
fatigue
headache
nausea
injection site reactions
hypercalcemia
orthostatic hypotension
leg cramps
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:bfsParent
|
gptkb:Eli_Lilly_and_Company
|
|
gptkbp:bfsLayer
|
3
|